A patient in her 60s was referred to the dermatology department for recurrent oral ulcerations. She did not report any history of skin disorders. She was treated for an advanced ALK-positive NSCLC with crizotinib for 7 months (500 mg/day). No other medication was reportedly prescribed. Two months after the initiation of treatment, she developed grade 2 stomatitis (according to the National Cancer Institute Common Terminology Criteria, version 4.0), with progressive occurrence of debilitating ulcers on the tongue and oral mucosa. The ulcers interfered with fluid/ food intake and had a negative impact on her quality of life. Oral examination revealed a combination of ulcerative lesions with characteristic papular/plaque-like lesions and reticular white streaks involving both keratinized (dorsum of the tongue) and nonkeratinized mucosae (buccal mucosa, lateral aspects of the tongue, mucosal aspect of the lip) [ Figure 1a and b]. These oral mucosal changes had developed in an isolated manner, without any involvement of the skin, nails, or genital areas. A mucosal biopsy showed focal parakeratosis with hypergranulosis and a lichenoid interface dermatitis, combining a superficial band-like T-cell infiltrate in the upper lamina propria together with vacuolar basal changes [ Figure 2 ]. Symptomatic management was started with topical high-potency corticosteroids (0.05% clobetasol propionate cream -Dermoval ® , twice a day), together with the promotion of optimal oral hygiene. After 1 month of therapy, the oral lesions had returned to grade 1, and the anticancer therapy was continued at the current dose [ Figure 3a and b].
Oral adverse events induced by new targeted anticancer therapies remain poorly characterized and are frequently described using nonspecific terminology (e.g. "stomatitis" or "mucositis"). However, targeted-therapy-related oral toxicities often display very characteristic changes that differ significantly from mucositis induced by chemotherapeutic agents [ Table 1 ]. This mainly includes mechanistic target of rapamycin kinase (mTOR) inhibitor-associated stomatitis (mIAS), stomatitis, and benign migratory glossitis associated with multitargeted kinase inhibitors of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors, oral aphthous-like lesions induced by epidermal growth factor receptor (EGFR) inhibitors, hyperpigmentation of the palate with imatinib, ibrutinib-related stomatitis, or hyperkeratotic lesions with B-rapidly accelerated fibrosarcoma (BRAF) inhibitors in monotherapy. 3 Moreover, oral lichenoid reactions have also been observed with a range of targeted therapies, notably with imatinib and to a lesser degree with rituximab. The overall incidence of such oral lichenoid lesions appears even higher with the newly developed immune checkpoint inhibitors. In this context, oral lichenoid reactions may occur alone or in association with cutaneous or nail involvement, as we have recently described with anti-programmed cell death 1 (PD-1) or anti-programmed cell death-ligand 1 (anti-PD-L1) therapies. 4 The only emergent oral mucosal toxicity associated with crizotinib is dysgeusia, which affects approximately 20% of patients treated with this drug. 3 Nonspecific stomatitis has been only reported sporadically in a subset of patients treated with this drug. Our case, as well as that recently reported by Ho and Chen, shows that a subset of eruptions induced by crizotinib may be due to a lichenoid reaction, either with skin or oral mucosal involvement. 2 However, the description of these lichenoid toxicities with crizotinib remains isolated until date and this must be confirmed over time. It may also be hypothesized that esophageal ulcerations, which have been described recently with this drug in several patients, may be related to a lichenoid inflammation. 5 The available histopathological analyses, however, do not support this theory. 5 Finally, although the overall incidence of skin rash seems to be higher, no skin or mucosal lichenoid reactions have been reported so far with the next-generation ALK inhibitors (e.g. alectinib, brigatinib). 1 In conclusion, practitioners should be aware of oral lichenoid reactions occurring in association with targeted therapies, including the ALK inhibitor crizotinib, which may require specific management with topical or systemic corticosteroids. 3, 4 Moreover, the follow-up of treated patients should include a systematic and regular oral examination. Finally, prospective evaluation of the oral region in patients treated with new-generation ALK inhibitors should also be promoted, to check whether this observation corresponds to a class effect or not.
